Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25498765 | 0.91 | ALDH1A1 (0.35) | VSIRMEN1NPC1ALDH1A1MAPT | |
| SCHEMBL29298721 | 0.91 | KDM4E (0.39) | MEN1NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL29298734 | 0.91 | KDM4E (0.39) | MEN1NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL25498700 | 0.89 | ALDH1A1 (0.36) | VSIRMEN1NPC1ALDH1A1MAPT | |
| SCHEMBL29298378 | 0.88 | VSIR (0.35) | VSIRMEN1NPC1ALDH1A1MAPT | |
| SCHEMBL29298042 | 0.88 | KDM4E (0.39) | MEN1NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL29298054 | 0.88 | KDM4E (0.39) | MEN1NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL29298116 | 0.87 | VSIR (0.38) | VSIRMEN1NPC1ALDH1A1MAPT | |
| SCHEMBL26313249 | 0.86 | LMNA (0.32) | MAPTKMT2A | |
| SCHEMBL29297920 | 0.86 | KDM4E (0.37) | MEN1NPC1ALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240237514-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME AND COMPOSITION FOR ORGANIC MATERIAL LAYER | LT MATERIALS CO., LTD. (KR) | 2024-07-11 | — | — | US | disclosed |
| US-20240237514-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME AND COMPOSITION FOR ORGANIC MATERIAL LAYER | LT MATERIALS CO., LTD. (KR) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240237514-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME AND COMPOSITION FOR ORGANIC MATERIAL LAYER | CYP1A1, CYP1B1, CYP2E1 | VSIR 4819/4885MEN1 338/4885NPC1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.